EcoDrugPlus

Calcium Voltage-Gated Channel Subunit Alpha1 C

Ensembl ID : ENSSLDG00000015301
Gene Symbol: CACNA1C
3 Cross references
213 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSSLDG00000023106
Gene Symbol: CACNA1D
4 Cross references
208 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSSLDG00000003664
Gene Symbol: CACNA1E
2 Cross references
212 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSSLDG00000012200
Gene Symbol: CACNA1E
3 Cross references
206 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSSLDG00000021840
Gene Symbol: CACNA1G
2 Cross references
196 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSSLDG00000003271
Gene Symbol: CNR1
4 Cross references
134 Possible Orthologues:

Cannabinoid Receptor 2

Ensembl ID : ENSSLDG00000002743
Gene Symbol: CNR2
1 Cross references
190 Possible Orthologues:

Cannabinoid Receptor 2-Like

Ensembl ID : ENSSLDG00000008157
Gene Symbol: LOC111651726
3 Cross references
190 Possible Orthologues:

Cannabinoid Receptor Type 1a

Ensembl ID : ENSSLDG00000011583
Gene Symbol: LOC111652937
4 Cross references
148 Possible Orthologues:

Cannabinoid Receptor Type 1a

Ensembl ID : ENSSLDG00000024218
Gene Symbol: LOC111661590
4 Cross references
148 Possible Orthologues:

Cannabinoid Receptor Type 1a

Ensembl ID : ENSSLDG00000004051
Gene Symbol: LOC111664532
4 Cross references
148 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSSLDG00000024254
Gene Symbol: CA12
3 Cross references
214 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).